Comparing Nvni Group (NASDAQ:NVNI) and Coeptis Therapeutics (NASDAQ:ZSQR)

Nvni Group (NASDAQ:NVNI) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Institutional & Insider Ownership

0.5% of Nvni Group shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 20.0% of Nvni Group shares are owned by insiders. Comparatively, 24.2% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Nvni Group has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.2, suggesting that its stock price is 120% less volatile than the S&P 500.

Profitability

This table compares Nvni Group and Coeptis Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nvni Group	N/A	N/A	N/A
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Earnings & Valuation

This table compares Nvni Group and Coeptis Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nvni Group	$35.23 million	0.30	-$20.22 million	$0.40	2.60
Coeptis Therapeutics	$1.36 million	142.24	-$11.92 million	($1.63)	-2.24

Coeptis Therapeutics has lower revenue, but higher earnings than Nvni Group. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Nvni Group, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Nvni Group and Coeptis Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nvni Group	1	1	0	0	1.50
Coeptis Therapeutics	1	0	0	0	1.00

Summary

Nvni Group beats Coeptis Therapeutics on 8 of the 12 factors compared between the two stocks.

About Nvni Group

Nvni Group Limited provides a business to business SaaS platform that offers cloud solutions. The company was incorporated in 2019 and is based in São Paulo, Brazil.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.